# A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

> **NCT06959537** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Axatilimab (SNDX-6352)
- **DRUG:** Retifanlimab

## Key facts

- **NCT ID:** NCT06959537
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-13
- **Primary completion:** 2027-01-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06959537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06959537, "A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06959537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*